이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Q-linea 과거 수익 실적

과거 기준 확인 0/6

Q-linea의 수입은 연평균 -8.6%의 비율로 감소해 온 반면, Medical Equipment 산업은 수입이 연평균 17%의 비율로 증가했습니다. 매출은 연평균 37.7%의 비율로 증가해 왔습니다.

주요 정보

-6.5%

수익 성장률

10.9%

EPS 성장률

Medical Equipment 산업 성장	6.2%
매출 성장률	32.6%
자기자본 수익률	-329.8%
순이익	-3,150.6%
다음 실적 업데이트	31 Oct 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Q-linea 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

OM:QLINEA 수익, 비용 및 수입 (SEK Millions )
날짜	수익	수익	G+A 비용
30 Jun 24	7	-225	206
31 Mar 24	8	-224	206
31 Dec 23	6	-229	215
30 Sep 23	6	-239	214
30 Jun 23	5	-249	221
31 Mar 23	8	-257	225
31 Dec 22	14	-269	226
30 Sep 22	18	-256	215
30 Jun 22	16	-246	208
31 Mar 22	16	-241	203
31 Dec 21	10	-231	195
30 Sep 21	6	-237	206
30 Jun 21	5	-236	204
31 Mar 21	1	-226	192
31 Dec 20	1	-219	184
30 Sep 20	0	-224	182
30 Jun 20	0	-210	171
31 Mar 20	1	-197	163
31 Dec 19	1	-177	147
30 Sep 19	1	-155	131
30 Jun 19	2	-149	124
31 Mar 19	1	-141	116
31 Dec 18	1	-128	104
30 Sep 18	2	-111	91
30 Jun 18	2	-97	79
31 Dec 17	2	-68	58
31 Dec 16	0	-60	51

양질의 수익: QLINEA 은(는) 현재 수익성이 없습니다.

이익 마진 증가: QLINEA 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: QLINEA 은(는) 수익성이 없으며 지난 5년 동안 연간 8.6% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 QLINEA 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: QLINEA 은(는) 수익성이 없어 지난 해 수익 성장을 Medical Equipment 업계( 41.1% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: QLINEA 현재 수익성이 없기 때문에 마이너스 자본 수익률( -167.32% )을 갖습니다.

Q-linea 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Q-linea AB (publ) to Report Q1, 2025 Results on May 03, 2025

First quarter 2024 earnings released: kr0.48 loss per share (vs kr2.10 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

Q-linea AB (publ) to Report First Half, 2024 Results on Jul 11, 2024

Recent updates

Consensus revenue estimates fall by 42%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Q-linea AB (publ) to Report Q1, 2025 Results on May 03, 2025

Q-linea AB (publ) Approves the Election of Jonas Jarvius as Members of the Board of Directors

Consensus revenue estimates increase by 49%

First quarter 2024 earnings released: kr0.48 loss per share (vs kr2.10 loss in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates increase by 24%, EPS downgraded

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings: EPS and revenues miss analyst expectations

Q-Linea AB Appoints Anders Ljunggren as Managing Director, Effective 1 March 2024

Q-linea AB (publ) Announces CEO Changes

Q-linea AB (publ) to Report First Half, 2024 Results on Jul 11, 2024

Q-linea AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Here's Why Q-linea (STO:QLINEA) Must Use Its Cash Wisely

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 27%

Price target decreased by 13% to kr10.00

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Q-Linea AB (Publ) Announces Jonas Jarvius to Step Down as CEO Before Summer 2024

Q-linea AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 262.885275 million.

New major risk - Share price stability

Consensus revenue estimates decrease by 40%, EPS upgraded

Q-linea AB (publ) Completes its 510(k) Application for US Market Approval

Second quarter 2023 earnings released: kr2.23 loss per share (vs kr2.53 loss in 2Q 2022)

Q-linea AB (publ) Announces First Patient Enrolls in Lifetimes

Consensus revenue estimates increase by 40%, EPS downgraded

Insufficient new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

CFO & Investor Relations Officer recently bought kr143k worth of stock

Full year 2022 earnings released: kr9.20 loss per share (vs kr8.19 loss in FY 2021)

Q-linea AB (publ) Announces CFO Changes, Effective May 1, 2023

Q-linea AB (publ) Prepare to Start Additional Testing for US 510(K) Application

Q-Linea Participates in Comparative Rapid AST Study

VP & Research Director recently bought kr241k worth of stock

Consensus revenue estimates fall by 21%

Q-linea AB (publ) to Report Q1, 2023 Results on May 04, 2023

Third quarter 2022 earnings released: kr2.03 loss per share (vs kr1.68 loss in 3Q 2021)

Consensus revenue estimates fall by 34%

Second quarter 2022 earnings released: kr2.53 loss per share (vs kr2.47 loss in 2Q 2021)

Consensus revenue estimates fall by 82%

Will Q-linea (STO:QLINEA) Spend Its Cash Wisely?

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Price target decreased to kr165

Q-linea AB (publ) Announces Marcus Storch Not Available for Re-Election as Member of Board of Directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

CEO & President recently bought kr480k worth of stock

Insufficient new directors

Now 22% undervalued after recent price drop

Price target decreased to kr165

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS and revenues miss analyst expectations

Q-linea (STO:QLINEA) Is In A Good Position To Deliver On Growth Plans

Forecast to breakeven in 2023

Third quarter 2021 earnings released: kr1.68 loss per share (vs kr1.80 loss in 3Q 2020)

Forecast to breakeven in 2023

Second quarter 2021 earnings released: kr2.47 loss per share (vs kr2.37 loss in 2Q 2020)

CEO & President recently sold kr14m worth of stock

Q-linea AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 301.4 million.

Q-linea AB (publ) Initiates US 510(k) Clinical Study for ASTar

Consensus forecasts updated

First quarter 2021 earnings released: kr2.34 loss per share (vs kr2.44 loss in 1Q 2020)

Full year 2020 earnings released: kr8.64 loss per share (vs kr7.74 loss in FY 2019)

Price target increased to kr185

Q-linea AB (publ) Receives First Order on ASTar

Full year 2020 earnings released: kr8.64 loss per share (vs kr7.74 loss in FY 2019)

Revenue beats expectations